Does the media favor VNDA or FBIO?

In the previous week, Fortress Biotech had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 3 mentions for Fortress Biotech and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Fortress Biotech's score of 0.47 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TTRX or FBIO?

In the previous week, Turn Therapeutics had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 5 mentions for Turn Therapeutics and 3 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.47 beat Turn Therapeutics' score of 0.42 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AMRN or FBIO?

In the previous week, Fortress Biotech had 1 more articles in the media than Amarin. MarketBeat recorded 3 mentions for Fortress Biotech and 2 mentions for Amarin. Amarin's average media sentiment score of 0.54 beat Fortress Biotech's score of 0.47 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FBIO or ZNTL?

In the previous week, Fortress Biotech and Fortress Biotech both had 3 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 1.07 beat Fortress Biotech's score of 0.47 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fortress Biotech (FBIO) Competitors

$2.52 -0.05 (-1.95%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.54 +0.02 (+0.60%)

As of 09/11/2026 07:59 PM Eastern

Compare

FBIO vs. IKT, VNDA, TTRX, AMRN, and ZNTL

Should you buy Fortress Biotech stock or one of its competitors? Fortress Biotech's main competitors and comparable companies include Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Turn Therapeutics (TTRX), Amarin (AMRN), and Zentalis Pharmaceuticals (ZNTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Fortress Biotech compare to Inhibikase Therapeutics?

Fortress Biotech (NASDAQ:FBIO) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Fortress Biotech has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Fortress Biotech has a net margin of 163.32% compared to Inhibikase Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Fortress Biotech had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Fortress Biotech and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.89 beat Fortress Biotech's score of 0.47 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Neutral
Inhibikase Therapeutics	Very Positive

Fortress Biotech has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$68.47M	1.23	$6.82M	$2.64	0.95
Inhibikase Therapeutics	$260K	1,255.86	-$48.26M	-$0.43	N/A

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 574.60%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 130.77%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Fortress Biotech beats Inhibikase Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Vanda Pharmaceuticals presently has a consensus target price of $13.70, indicating a potential upside of 169.16%. Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 574.60%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has a net margin of 163.32% compared to Vanda Pharmaceuticals' net margin of -127.41%. Fortress Biotech's return on equity of 83.47% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Fortress Biotech	163.32%	83.47%	42.98%

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Fortress Biotech had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 3 mentions for Fortress Biotech and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Fortress Biotech's score of 0.47 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fortress Biotech has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.63	N/A
Fortress Biotech	$68.47M	1.23	$6.82M	$2.64	0.95

Vanda Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Summary

Fortress Biotech beats Vanda Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Fortress Biotech has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Fortress Biotech	$68.47M	1.23	$6.82M	$2.64	0.95

Turn Therapeutics presently has a consensus target price of $8.00, indicating a potential downside of 36.96%. Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 574.60%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Turn Therapeutics had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 5 mentions for Turn Therapeutics and 3 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.47 beat Turn Therapeutics' score of 0.42 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.5% of Fortress Biotech shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Fortress Biotech has a net margin of 163.32% compared to Turn Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Fortress Biotech	163.32%	83.47%	42.98%

Summary

Fortress Biotech beats Turn Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Fortress Biotech compare to Amarin?

Amarin (NASDAQ:AMRN) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, Fortress Biotech had 1 more articles in the media than Amarin. MarketBeat recorded 3 mentions for Fortress Biotech and 2 mentions for Amarin. Amarin's average media sentiment score of 0.54 beat Fortress Biotech's score of 0.47 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fortress Biotech has a net margin of 163.32% compared to Amarin's net margin of -14.56%. Fortress Biotech's return on equity of 83.47% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Fortress Biotech	163.32%	83.47%	42.98%

Fortress Biotech has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.36	-$38.80M	-$0.99	N/A
Fortress Biotech	$68.47M	1.23	$6.82M	$2.64	0.95

Amarin has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Amarin presently has a consensus target price of $13.00, suggesting a potential downside of 5.80%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 574.60%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

22.3% of Amarin shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Fortress Biotech beats Amarin on 13 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Zentalis Pharmaceuticals?

Fortress Biotech (NASDAQ:FBIO) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Fortress Biotech has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$68.47M	1.23	$6.82M	$2.64	0.95
Zentalis Pharmaceuticals	$67.43M	3.73	-$137.06M	-$1.95	N/A

Fortress Biotech presently has a consensus price target of $17.00, suggesting a potential upside of 574.60%. Zentalis Pharmaceuticals has a consensus price target of $6.75, suggesting a potential upside of 92.31%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Fortress Biotech and Fortress Biotech both had 3 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 1.07 beat Fortress Biotech's score of 0.47 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market.

Fortress Biotech has a net margin of 163.32% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

96.5% of Fortress Biotech shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Fortress Biotech beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBIO vs. The Competition

Export

Metric	Fortress Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84.05M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.17%
P/E Ratio	0.95	799.75	274.94	25.36
Price / Sales	1.23	966.93	686.57	116.78
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	1.26	10.39	10.33	6.20
Net Income	$6.82M	$2.85B	$3.50B	$358.50M
7 Day Performance	-7.35%	-3.61%	-3.32%	-2.35%
1 Month Performance	-15.44%	0.72%	-0.53%	-3.23%
1 Year Performance	-35.22%	3.61%	23.51%	8.79%

Fortress Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBIO Fortress Biotech	2.2351 of 5 stars	$2.52 -1.9%	$17.00 +574.6%	-35.2%	$84.05M	$68.47M	0.95	170
IKT Inhibikase Therapeutics	2.2966 of 5 stars	$2.47 -1.2%	$5.40 +118.6%	+50.0%	$344.66M	$260K	N/A	6	Positive News
VNDA Vanda Pharmaceuticals	3.0221 of 5 stars	$5.23 -3.8%	$13.70 +162.2%	+12.9%	$324.97M	$216.10M	N/A	290	Positive News
TTRX Turn Therapeutics	1.5132 of 5 stars	$10.18 +3.8%	$8.00 -21.4%	N/A	$303.11M	N/A	N/A	2	News Coverage Analyst Upgrade
AMRN Amarin	0.9451 of 5 stars	$13.55 -0.6%	$13.00 -4.1%	-8.1%	$288.58M	$213.65M	N/A	360

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBIO) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortress Biotech (FBIO) Competitors

FBIO vs. IKT, VNDA, TTRX, AMRN, and ZNTL

How does Fortress Biotech compare to Inhibikase Therapeutics?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Summary

How does Fortress Biotech compare to Turn Therapeutics?

Summary

How does Fortress Biotech compare to Amarin?

Summary

How does Fortress Biotech compare to Zentalis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortress Biotech (FBIO) Competitors

FBIO vs. IKT, VNDA, TTRX, AMRN, and ZNTL

How does Fortress Biotech compare to Inhibikase Therapeutics?

Which has more volatility & risk, FBIO or IKT?

Is FBIO or IKT more profitable?

Do institutionals & insiders have more ownership in FBIO or IKT?

Does the media refer more to FBIO or IKT?

Which has better valuation and earnings, FBIO or IKT?

Do analysts prefer FBIO or IKT?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Do analysts prefer VNDA or FBIO?

Is VNDA or FBIO more profitable?

Do institutionals and insiders believe in VNDA or FBIO?

Does the media favor VNDA or FBIO?

Which has better valuation and earnings, VNDA or FBIO?

Which has more volatility and risk, VNDA or FBIO?

Summary

How does Fortress Biotech compare to Turn Therapeutics?

Which has preferable earnings & valuation, TTRX or FBIO?

Do analysts rate TTRX or FBIO?

Does the media favor TTRX or FBIO?

Do insiders and institutionals believe in TTRX or FBIO?

Is TTRX or FBIO more profitable?

Summary

How does Fortress Biotech compare to Amarin?

Does the media prefer AMRN or FBIO?

Is AMRN or FBIO more profitable?

Which has stronger earnings & valuation, AMRN or FBIO?

Which has more volatility & risk, AMRN or FBIO?

Do analysts rate AMRN or FBIO?

Do insiders & institutionals hold more shares of AMRN or FBIO?

Summary

How does Fortress Biotech compare to Zentalis Pharmaceuticals?

Which has stronger earnings & valuation, FBIO or ZNTL?

Do analysts rate FBIO or ZNTL?

Does the media refer more to FBIO or ZNTL?

Which has more volatility and risk, FBIO or ZNTL?

Is FBIO or ZNTL more profitable?

Do insiders and institutionals have more ownership in FBIO or ZNTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools